In other words, the agonistic antibodies against KIR2DL4 would be useful for allergy therapy, similar to the anti-IgE antibody omalizumab clinically utilized to neutralize IgE in blood, and eliminate of FcɛRI-mediated function and control mast cell-mediated allergic reactions [56]. The gene discussed is KIR2DL4; the disease is allergic disease.